The Law Offices Of

Dallas, Texas USA
Specializing in helping people since 1961

Fen-Phen: Ongoing Studies

These forty slides describe the ongoing studies of Fen-Phen and the health problems associated with the drug. These slides were included in a presentation given by David Terry, to a group of lawyers.

Start the Slides

Table of Contents

1. Fen-Phen: Ongoing Studies
2. Fen-Phen: Ongoing Studies
3. Weintraub's '84 Study Weintraub et al, Arch Intern Med, Vol. 144: 1143-1148 (1984)
4. Weintraub's '92 Report of Long Term Study Weintraub, et al, Long Term Weight Control Study (I-VII), Clin Pharmacol Ther, Vol.51:586-646 (1992)
5. Weintraub's '92 Report of Long Term Fen-Phen Study Weintraub, et al, Long Term Weight Control Study (I-VII), Clin Pharmacol Ther, Vol.51:586-646 (1992)
6. Complications of Fen-Phen
7. Heart Valve Complications
8. Heart Valve Complications What We Know August '97 NEJM Study Connolly, HM, et al, Valvular Heart Disease Associated With Fenfluramine-Phentermine, New England J. of Medicine, 337:9, 581-88 (1997).
9. Heart Valve Complications What We Don't Know From August '97 NEJM Study
10. Heart Valve Complications What We Know
11. Heart Valve Complications What We Don't Know.From Published Studies.
12. Heart Valve Complications
13. Heart Valve Complications
14. Heart Valve Complications FDA Analysis
15. Heart Valve Complications FDA Analysis
16. Heart Valve Complications FDA Analysis
17. Heart Valve Complications FDA Analysis
18. Heart Valve Complications FDA Analysis
19. Heart Valve Complications FDA Analysis Counts of Subjects
20. Heart Valve Complications FDA Analysis Absolute Risk of Valvulopathy
21. Heart Valve Complications What We Know FDA Analysis Relative Risk
22. Heart Valve Complications What We Know FDA Analysis Relative Risk: Aortic Valvulopathy
23. Heart Valve Complications FDA Analysis Background Rate of Valvulopathy
24. Heart Valve Complications
25. Wyeth-Ayerst Cardiovascular Assessment Expert Panel
26. Primary Pulmonary Hypertension

27. Primary Pulmonary Hypertension What We Know N.E.J.M. '96 Study.Abenhaim, M.D., et al, Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension, The New England J. of Medicine, 335:9, 609-616
28. Primary Pulmonary Hypertension What We Know.N.E.J.M. '96 Study Abenhaim, M.D., et al, Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension, The New England J. of Medicine, 335:9, 609-616
29. Primary Pulmonary Hypertension What We Don't Know From N.E.J.M. '96 Study.Abenhaim, M.D., et al, Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension, The New England J. of Medicine, 335:9, 609-616
30. Primary Pulmonary Hypertension What We Know From J.A.M.A. Study McCann, U.D., et al, Brain and Serotonin Neurotoxicity and Primary Pulmonary Hypertension From Fenfluramine and Dexfenfluramine, A Systematic Review of the Evidence, JAMA, 278:8, 666-672 (1997).
31. Primary Pulmonary Hypertension
32. Primary Pulmonary Hypertension Ongoing Studies
33. Neurotoxic Effects
34. Neurotoxic Effects in Animals What We Know From J.A.M.A. Study McCann, U.D., et al, Brain and Serotonin Neurotoxicity and Primary Pulmonary Hypertension From Fenfluramine and Dexfenfluramine, A Systematic Review of the Evidence, JAMA, 278:8, 666-672 (1997).
35. Neurotoxic Effects in Animals What We Don't Know From J.A.M.A. Study McCann, U.D., et al, Brain and Serotonin Neurotoxicity and Primary Pulmonary Hypertension From Fenfluramine and Dexfenfluramine, A Systematic Review of the Evidence, JAMA, 278:8, 666-672 (1997).
36. Neurotoxic Effects in Humans
37. Neurotoxic Effects in Humans Wyeth-Ayerst Phase 4 Study
38. Neurotoxic Effects in Humans Wyeth-Ayerst Phase 4 Study
39. Neurotoxic Effects in Humans Wyeth-Ayerst Phase 4 Study
40. Fen-Phen: Ongoing Studies

[ Home | Our Firm | Our Practice | Our Lawyers | Contact Us ]
[ Common Questions | Some Cases | Other Links ]
[ Consumer Alerts | Fen-Phen | Duract | Butamben | Protein | Prescription Drugs ]

Copyright © 1997-2002. All Rights Reserved.
Send comments about web site to: Webmaster